Infectious Diseases - HIV
Dr. Nancy Reid, MHA, DHSc, PA-C
Daily pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC) has been shown to reduce HIV-1 transmission in several different populations, including men who have sex with men (MSM), people who inject drugs, heterosexual men and women, transgender patients, and serodiscordant couples. However, difficulty adhering to daily dosing is a barrier to some patients accepting PrEP. The option of using event-driven HIV prophylaxis with TDF/FTC rather than committing to daily dosing can be an attractive alternative to many patients who might otherwise decline PrEP due to perceiving their risk to be lower in general and higher only centered around specific events or travel. Identifying whether taking an “on demand,” event-centered regimen of TDF/FTC is similarly effective to daily dosing in preventing the contraction of HIV is necessary before making such a recommendation to patients at increased event-centered risk.
Boehringer, Agustina G. MS, PA-C
"Effectiveness of Event-Driven HIV Prophylaxis (On Demand PrEP),"
Lynchburg Journal of Medical Science: Vol. 1
, Article 4.
Available at: https://digitalshowcase.lynchburg.edu/dmscjournal/vol1/iss3/4
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.